Showing results (51-60 of 638) with videos related to

Sort By:
Pageof 64
Lancet (London, England)|December 12, 1992
Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemiaF Lo Coco, D Diverio, P P Pandolfi, et al.
Tumori|August 31, 1987
Secondary acute non lymphoid leukemia in patients treated for non Hodgkin's lymphoma: no risk of therapy-related ANLL after PROVECIP scheduleG Cimino, A P Anselmo, C Cartoni, et al.
Haematologica|March 1, 1990
Immunoglobulin heavy chain and T-cell receptor beta chain gene rearrangements in acute non lymphoid leukemiaR Leone, F Lo Coco, G De Rossi, et al.
British Journal of Haematology|November 1, 1996
Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferonM C Petti, R Latagliata, G Avvisati, et al.
Leukemia Research|January 1, 1984
PHA-ICC, ADCC and NK in patients with ANLL in CR: human fibroblastic interferon fails to increase NK-active cell frequencyL Fontana, G De Rossi, G De Sanctis, et al.
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|January 1, 1985
Turnover of alpha-2-antiplasmin in patients with acute promyelocytic leukemiaL H Kahle, G Avvisati, R J Lamping, et al.
Leukemia|November 1, 1993
Occurrence of a Ki-1-positive anaplastic large-cell lymphoma in a patient with Ph' positive chronic myelogenous leukemia successfully treated by alpha-interferonE Montefusco, F Lo Coco, V L Burgio, et al.
Blood|July 15, 1993
Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangementsF Lo Coco, P G Pelicci, F D'Adamo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1993
P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphomaM Martelli, C Guglielmi, S Coluzzi, et al.
European Journal of Haematology|March 1, 1991
Chronic myeloid leukaemia lymphoid blast crisis. Relevance of molecular analysis at the bcr and immunoglobulin heavy chain gene level in monitoring response to therapy and residual diseaseF Lo Coco, D Diverio, M Frontani, et al.
Pageof 64